GLP Tracker
Orforglipron Status: Trials, Approvals, and What Changed
Eli Lilly's oral GLP-1 receptor agonist is moving through late-stage trials. Here's where the data stands, what the timelines look like, and how this compound differs from approved branded drugs.
Orforglipron is an investigational, non-peptide oral GLP-1 receptor agonist developed by Eli Lilly. As of mid-2025, it has completed Phase 2 trials showing meaningful weight loss and glycemic results, and multiple Phase 3 trials are active under the ATTAIN and ACHIEVE programs. Orforglipron has not received FDA approval in any form; no branded version is currently on the market.
What Is Orforglipron?
Orforglipron (development code LY3502970) is a small-molecule, non-peptide GLP-1 receptor agonist taken orally once daily. Unlike semaglutide, which is a peptide and requires specific absorption conditions even in its oral Rybelsus form, orforglipron is a true small molecule. That distinction matters for manufacturing cost, storage, and absorption consistency, all of which Lilly has cited as development rationale.
Because it is not a peptide, orforglipron does not require the fasting-and-water protocol associated with oral semaglutide. It activates the same GLP-1 receptor pathway that drives the effects seen across the GLP class: appetite suppression, slowed gastric emptying, and improved insulin secretion in a glucose-dependent manner. All of this remains under active clinical investigation; no efficacy or safety conclusions apply outside the controlled trial settings described below.
Orforglipron is a research-stage compound. It is not FDA approved, it has no branded name, and it is not equivalent to any currently marketed prescription drug. Approved GLP-1 products such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are separate branded drugs with their own regulatory histories.
Phase 2 Readouts: What the Numbers Showed
The pivotal Phase 2 data for orforglipron in obesity was published in The New England Journal of Medicine in June 2023. The randomized, double-blind, placebo-controlled trial enrolled 272 adults with obesity or overweight plus at least one weight-related condition. Over 36 weeks, participants in the highest dose cohort achieved a mean weight reduction of approximately 14.7 percent from baseline, compared with 2.3 percent in the placebo group.
A separate Phase 2 trial in adults with type 2 diabetes, also published in NEJM in June 2023, enrolled 383 participants across multiple dose groups over 26 weeks. Participants receiving the highest orforglipron dose achieved a mean HbA1c reduction of 2.1 percentage points from a baseline of roughly 8.0 percent. Fasting glucose and body weight also declined across active dose groups. Gastrointestinal adverse events, primarily nausea, vomiting, and diarrhea, were the most common side effects and were consistent with the GLP-1 class profile.
These Phase 2 results positioned orforglipron as competitive with injectable GLP-1 agents on a percentage-weight-loss basis, which was notable given the oral route. However, Phase 2 data in a few hundred participants over less than a year does not establish long-term safety or cardiovascular outcomes. Those questions are what the Phase 3 program is designed to answer.
Phase 3 Program: ATTAIN and ACHIEVE Trial Status
Eli Lilly launched two Phase 3 umbrella programs for orforglipron. ATTAIN covers obesity indications, and ACHIEVE covers type 2 diabetes management. As of early 2025, multiple trials within both programs are actively enrolling or in follow-up. The ATTAIN-1 trial (NCT05861557) is a 72-week randomized controlled trial in adults with obesity or overweight, targeting approximately 3,000 participants. ATTAIN-2 and ATTAIN-3 extend the program to include cardiovascular outcomes and specific comorbidity populations.
The ACHIEVE program mirrors this structure for type 2 diabetes. ACHIEVE-1 (NCT05803421) is a 40-week trial comparing orforglipron against placebo and an active comparator in adults with type 2 diabetes inadequately controlled on metformin. Lilly has also initiated a cardiovascular outcomes trial within the ACHIEVE umbrella, which is required by FDA for new diabetes drugs that reach a certain exposure threshold.
Topline results from the first ATTAIN and ACHIEVE trials were anticipated in late 2025, with full data readouts expected to follow. Lilly has publicly stated it intends to file a New Drug Application with the FDA, though no submission date has been formally confirmed as of this writing. Phase 3 completion and NDA filing are distinct milestones; regulatory review typically adds 12 months or more after a complete submission.
Regulatory Milestones: Where Does Approval Stand?
Orforglipron has not been submitted for FDA approval as of mid-2025. It holds no Breakthrough Therapy designation, Fast Track designation, or Priority Review status that has been publicly disclosed. The compound is investigational, meaning it can only be administered legally in the United States within the context of an approved clinical trial under an Investigational New Drug application.
If Lilly files an NDA and the FDA grants standard review, the review clock runs 12 months from acceptance. Priority Review would shorten that to 6 months, but Priority Review is granted by the FDA based on whether the drug offers a significant improvement over available therapies, a determination that has not yet been made. The earliest plausible approval window, assuming positive Phase 3 data and a 2025 or early 2026 NDA filing, would be 2026 to 2027. That timeline is speculative and depends on data quality, completeness of the submission, and FDA workload.
Any approved version of orforglipron would carry a branded name assigned by Lilly and approved by the FDA. That branded drug would be a prescription medication dispensed through licensed pharmacies. Research-chemical versions sold online under the name orforglipron are not that product, are not FDA approved, and fall outside any regulatory oversight framework.
What Changed in 2024 and 2025
In May 2024, Lilly reported that ATTAIN-1 enrollment had completed ahead of schedule, which the company attributed to strong site performance and patient interest. Lilly also expanded the ATTAIN program to include an adolescent cohort, reflecting the FDA's increasing focus on pediatric obesity data as a condition of adult approvals in the GLP class.
In early 2025, Lilly disclosed that the cardiovascular outcomes trial within the ATTAIN program had reached its target enrollment. Cardiovascular outcomes trials in the GLP class typically run three to five years, so full CVOT data for orforglipron is not expected before 2028 at the earliest. However, FDA approval for obesity does not require a completed CVOT upfront; a post-market commitment is the more common regulatory path, as seen with semaglutide's Wegovy approval in 2021.
Lilly also presented additional Phase 2 subgroup analyses at the American Diabetes Association Scientific Sessions in 2024, showing consistent HbA1c and weight effects across age, sex, and baseline BMI subgroups. These analyses were exploratory and hypothesis-generating, not confirmatory. The Phase 3 trials remain the primary evidence base for any future regulatory decision.
How Orforglipron Compares to Approved GLP-1 Drugs
The FDA has approved several GLP-1 class drugs. Semaglutide is approved as Ozempic (injectable, type 2 diabetes), Wegovy (injectable, obesity and cardiovascular risk reduction), and Rybelsus (oral tablet, type 2 diabetes). Tirzepatide, a dual GIP/GLP-1 agonist, is approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). These are distinct branded prescription drugs with full prescribing information, post-market safety data, and established supply chains.
Orforglipron's potential differentiation, if it reaches approval, would center on its small-molecule oral formulation without the absorption restrictions of Rybelsus. Whether that translates to a clinical or commercial advantage depends on Phase 3 efficacy data, the final label, and pricing. None of those factors are settled. Comparing an investigational compound to approved drugs based on Phase 2 data alone carries significant uncertainty.
Research-chemical peptides sold under GLP-1 compound names online are not interchangeable with approved branded drugs and are not subject to the manufacturing controls, purity testing, or pharmacovigilance systems that apply to FDA-approved products. Orforglipron specifically is a small molecule, not a peptide, which adds another layer of distinction from the peptide research-chemical market.
Considering a GLP-1 option?
Retatrutide is not FDA-approved for any indication. If you want a legitimate, prescribed path, talk to a licensed provider about approved GLP-1 options.
Check eligibility for physician-supervised GLP-1 programsWe may earn a commission if you buy through this link.
Frequently asked questions
Has orforglipron been approved by the FDA?
No. As of mid-2025, orforglipron has not been approved by the FDA for any indication. It remains an investigational compound in Phase 3 clinical trials. Eli Lilly has not yet filed a New Drug Application. Any approval, if it occurs, would apply to a specific branded prescription drug, not to research-chemical versions sold online.
How does orforglipron differ from semaglutide or tirzepatide?
Semaglutide and tirzepatide are peptide-based compounds. Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor. Semaglutide is FDA approved as Ozempic, Wegovy, and Rybelsus; tirzepatide is approved as Mounjaro and Zepbound. Orforglipron has no approved form. Its small-molecule structure means it does not require the fasting protocol associated with oral semaglutide (Rybelsus), though this has not been evaluated in head-to-head Phase 3 trials.
When might Phase 3 results for orforglipron be available?
Topline results from the first ATTAIN and ACHIEVE Phase 3 trials were anticipated in late 2025, based on Lilly's publicly stated timelines and trial completion schedules on ClinicalTrials.gov. Full data publication and any NDA filing would follow those readouts. Regulatory review, if a filing occurs, typically takes 12 months under standard review. These timelines are subject to change based on data quality and FDA scheduling.
Sources
- Wharton et al., 2023, New England Journal of Medicine (Phase 2 obesity trial) Phase 2 RCT weight loss data, 272 participants
- Rosenstock et al., 2023, New England Journal of Medicine (Phase 2 diabetes trial) Phase 2 RCT HbA1c and weight data, 383 participants
- ATTAIN-1 Phase 3 Trial Registration, ClinicalTrials.gov Phase 3 obesity trial registration and status
- ACHIEVE-1 Phase 3 Trial Registration, ClinicalTrials.gov Phase 3 type 2 diabetes trial registration and status
Related reading
Medical disclaimer: This status report is educational and informational only and is not medical advice, diagnosis, or treatment. Retatrutide and the GLP-class research compounds discussed here may not be approved by the FDA for human use outside prescribed clinical contexts, and vendor-sourced material has not been evaluated by the FDA for safety, efficacy, or quality. Always consult a licensed physician or pharmacist before making any health-related decision.